SCHEMBL15480583

SCHEMBL15480583

CN(C)c1nc2cc(S(=O)(=O)Nc3ccc(C(=O)NO)cc3)ccc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 10/20 0.50
HDAC8 Q9BY41 5/20 0.50
HDAC3 O15379 3/20 0.50
HDAC11 Q96DB2 2/20 0.50
TRPV1 Q8NER1 1/20 0.48
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
RECQL P46063 2/20 0.45
HDAC1 Q13547 3/20 0.43
ALDH1A1 P00352 3/20 0.43
BRPF1 P55201 1/20 0.43
HDAC2 Q92769 2/20 0.43
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PHGDH O43175 1/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480586 0.86 ALDH1A1 (0.60) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL15480642 0.83 ALDH1A1 (0.47) HDAC6HDAC8HDAC3MAPTKDM4E
SCHEMBL15480582 0.83 HDAC6 (0.50) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL15480564 0.83 MAPT (0.51) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL15482249 0.81 HDAC6 (0.47) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL23054872 0.79 TRPV1 (0.47) HDAC6HDAC8HDAC3HDAC11TRPV1
SCHEMBL15480555 0.76 HDAC6 (0.52) HDAC6HDAC8HDAC3HDAC11MAPT
SCHEMBL15482206 0.74 HDAC6 (0.68) HDAC6HDAC8HDAC3HDAC11MAPT
SCHEMBL15482263 0.73 ALDH1A1 (0.57) HDAC6HDAC8HDAC3HDAC11MAPT
SCHEMBL15480578 0.73 HDAC8 (0.48) HDAC6HDAC8HDAC3HDAC11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC6 10/4885HDAC8 4/4885HDAC3 1/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC6 10/4885HDAC8 4/4885HDAC3 1/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC6 10/4885HDAC8 4/4885HDAC3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.